We appreciate FDA’s support in designating REVASCOR both RMAT and RPD status, a recognition of the potential impact of our therapy on the long-term adverse outcomes of these desperately ill children.

The study, “Expression and Diagnostic Value of miR-3591-5p in Patients with Congenital Heart Disease-Associated Pulmonary Arterial Hypertension,” was published in Lung. PAH is marked by high blood ...

Congenital heart defects are the most common form of human birth defect, but we still don’t fully understand what causes them. Previous research had suggested that some heart defects could be ...

The size of the national population of patients with grown-up congenital heart disease (GUCH) is uncertain, but since 80–85% of patients born with congenital heart disease now survive to adulthood ...

The advances in the peri-operative management of congenital heart defects have substantially improved the survival of infants over the last few decades, reaching >95% survival in the reports of the ...

Dec. 4, 2024 — Women who have a high genetic risk of depression are more likely to develop heart disease, researchers have ... The Heart Has Its Own 'Brain' Dec. 4, 2024 — New research shows ...

AIM To investigate the effect of several types of congenital heart disease (CHD) on nutrition and growth. PATIENTS AND METHODS The prevalence of malnutrition and growth failure was investigated in 89 ...

Perth Zoo has shared a touching tribute after one of its beloved Galapagos Tortoises died this week after a long health ...